507 related articles for article (PubMed ID: 14722257)
1. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
Auwerx J; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
[TBL] [Abstract][Full Text] [Related]
2. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
[TBL] [Abstract][Full Text] [Related]
3. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
5. Comparison of DNA polymerase activities between recombinant feline immunodeficiency and leukemia virus reverse transcriptases.
Operario DJ; Reynolds HM; Kim B
Virology; 2005 Apr; 335(1):106-21. PubMed ID: 15823610
[TBL] [Abstract][Full Text] [Related]
6. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
7. Intramolecular chimeras of the p51 subunit between HIV-1 and FIV reverse transcriptases suggest a stabilizing function for the p66 subunit in the heterodimeric enzyme.
Tasara T; Amacker M; Hübscher U
Biochemistry; 1999 Feb; 38(5):1633-42. PubMed ID: 9931031
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory RNA ligand to reverse transcriptase from feline immunodeficiency virus.
Chen H; McBroom DG; Zhu YQ; Gold L; North TW
Biochemistry; 1996 May; 35(21):6923-30. PubMed ID: 8639644
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.
Pelemans H; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2000 May; 57(5):954-60. PubMed ID: 10779379
[TBL] [Abstract][Full Text] [Related]
10. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases.
Amacker M; Hübscher U
J Mol Biol; 1998 May; 278(4):757-65. PubMed ID: 9614940
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate.
Quiñones-Mateu ME; Soriano V; Domingo E; Menéndez-Arias L
Virology; 1997 Sep; 236(2):364-73. PubMed ID: 9325244
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
14. The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A.
Auwerx J; Rodríguez-Barrios F; Ceccherini-Silberstein F; San-Félix A; Velázquez S; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
Mol Pharmacol; 2005 Sep; 68(3):652-9. PubMed ID: 15961674
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
[TBL] [Abstract][Full Text] [Related]
16. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
17. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
18. The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
Galilee M; Alian A
PLoS Pathog; 2018 Jan; 14(1):e1006849. PubMed ID: 29364950
[TBL] [Abstract][Full Text] [Related]
19. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses.
Rattanabunyong S; Choengpanya K; Suwattanasophon C; Kiriwan D; Wolschann P; Lamtha T; Shaikh AR; Rattanasrisomporn J; Choowongkomon K
J Vet Sci; 2023 Sep; 24(5):e67. PubMed ID: 38031646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
